Mel Evans/AP Photo Though it was a very difficult year for drugmakers, with the SPDR S&P Pharmaceuticals ETFlosing just shy of a quarter of its value, the same can't be said of healthcare conglomerate Johnson & Johnson, a company that leans heavily on its pharmaceutical segment for its growth and gross margin. Through Dec. 28, J&J is up a healthy 12% year to date. While it's always nice to celebrate a good year, it's also important to keep your eyes on the horizon, because Wall Street places far...
The 4 major catalysts awaiting one of the biggest drug companies in 2017
Business Insider - 30 Dec 2016 04:15
Mel Evans/AP Photo Though it was a very difficult year for drugmakers, with the SPDR S&P Pharmaceuticals ETFlosing just shy of a quarter of its value, the same can't be said of healthcare conglomerate Johnson & Johnson, a company that leans heavily on its pharmaceutical segment for its growth and gross margin. Through Dec. 28, J&J is up a healthy 12% year to date. While it's always nice to celebrate a good year, it's also important to keep your eyes on the horizon, because Wall Street places far...
Share this Article
Recommended